This inventor holds 9 USPTO granted patents and 1 published patent application. Top assignees: Klinge Pharma Gmbh, Astellas Deutschland Gmbh, Astellas Pharma Gmbh. Active years: 2002-2008.
Company Filing History:
5 out of 23 
2 out of 6 
2 out of 424 
Years Active: 2002-2008
Title: The Innovations of Barbara Schein: A Pioneer in Cytostatic and Immunosuppressive Agents
Introduction
Barbara Schein, an accomplished inventor based in Neufahrn, Germany, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of nine patents, Schein's work focuses primarily on developing innovative compounds that serve as cytostatic and immunosuppressive agents. Her research and inventions have the potential to impact the treatment of various types of tumors and autoimmune diseases.
Latest Patents
Schein's latest patents include pivotal inventions such as "Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents." This invention introduces new pyridylalkane, alkene, and alkine acid amides substituted with an aryl and/or heteroaryl residue. The compounds are significant in the medical field for their applications in therapies for tumor treatment and autoimmunity management. Another notable patent from Schein encompasses "Pyridyl alkane acid amides as cytostatics and immunosuppressives." This patent further explores the production of these compounds and their utility in creating medicaments aimed at treating tumors and effectively managing immune responses.
Career Highlights
Throughout her career, Barbara Schein has collaborated with various esteemed organizations that have enhanced her professional trajectory. She worked at Klinge Pharma GmbH and Astellas Deutschland GmbH, where she focused on drug development and innovation in the pharmaceutical sector. Her expertise in the synthesis of pharmaceutical compounds has positioned her as a key innovator in her field.
Collaborations
Schein has collaborated with notable professionals such as Elfi Biedermann and Max Hasmann. These partnerships have played a crucial role in fostering an environment of innovation and advancing research within the pharmaceutical industry. The collaborations have not only contributed to Schein’s advancements but have also facilitated the development of groundbreaking medicinal applications.
Conclusion
Barbara Schein stands out as a prominent figure in the realm of pharmaceutical innovations. Her patented inventions, particularly in the categories of cytostatics and immunosuppressives, underscore her commitment to enhancing therapeutic approaches for cancers and autoimmune conditions. As her work continues to evolve, Schein’s contributions are likely to leave a lasting impact on the medical community and the future of pharmaceutical science.